HOME ·

02005.HK

SSY GROUP (02005.HK): Baloxavir Marboxil API Approved for Registration, Becoming the Third Domestic Enterprise with Such Approval
Tags：
SSY Group02005.HKdrug registration approval
2026-07-13
SSY GROUP (02005.HK): Propylthiouracil Tablets and Calcium Gluconate and Sodium Chloride Injection Obtain Drug Registration Approvals, Deemed to Have Passed Consistency Evaluation
Tags：
SSY Group02005.HKdrug registration approval
2026-07-10
SSY GROUP (02005.HK): 95 Varieties Included in National Essential Medicines List (2026 Edition)
Tags：
SSY Group02005.HKPharmaceutical Updates
2026-07-10
SSY Group Limited(02005.HK): Methocarbamol Tablets Approved for Marketing; Phloroglucinol API Granted Registration
Tags：
SSY Group Limited02005.HK
2026-07-02
SSY Group (02005.HK): Trustee Acquires 1 Million Shares Under Restricted Share Incentive Scheme
Tags：
SSY Group02005.HKShare purchase
2026-06-24
SSY GROUP(02005.HK): Trustee Purchases 2 Million Shares Under Restricted Share Award Scheme at Average Price of HK$2.1585
Tags：
SSY Group02005.HKShare Award Scheme
2026-06-23
SSY GROUP(02005.HK): NMPA Grants Manufacturing Approval for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution
Tags：
SSY Group02005.HKmanufacturing registration approval certificate
2026-06-22
SSY Group(02005.HK): Trustee Purchases 380,000 Shares on Open Market Under Restricted Share Award Scheme at Average Price of HK$2.2124
Tags：
SSY Group02005.HKShare Buyback Scheme
2026-06-17
SSY Group Signs Letter of Intent with Longhai Pharma for Four Biosimilars Including Ustekinumab and Dupilumab
Tags：
SSY Group02005.HKtechnology transfer
2026-06-05
SSY Group (02005.HK) Secures Production Approval for Four Drugs; Second Domestic Firm to Launch Emedastine Difumarate Eye Drops
Tags：
SSY Group02005.HKdrug production registration approval
2026-05-21
SSY Group (02005.HK): Obtains Production Registration Approvals for Three Products; Fat-Soluble Vitamin Injection Approved as First Domestic Enterprise
Tags：
SSY Group02005.HKConsistencyEvaluation
2026-05-06
SSY Group (02005.HK): Diltiazem Hydrochloride for Injection and Propranolol Hydrochloride Injection Obtain Drug Production Registration Approvals
Tags：
SSY Group02005.HKdrug production registration approval
2026-04-27
SSY GROUP (02005.HK): Calcium Chloride API Approved for Registration by NMPA
Tags：
SSY Group02005.HKPharmaceuticalAPI
2026-03-19
SSY GROUP(02005.HK): Bumetanide API Approved by NMPA
Tags：
SSY Group02005.HKAPI
2026-03-16
SSY Group Limited (02005.HK): Calcium Levofolinate for Injection Approved, Deemed to Have Passed Consistency Evaluation
Tags：
SSY Group02005.HKdrug production registration approval
2026-03-06
SSY Group Limited (02005.HK): Obtains Drug Production Registration Approval for Doxapram Hydrochloride Injection, First Approved in China
Tags：
SSY Group02005.HKnew drug launch
2026-03-03
SSY Group(02005.HK): Two APIs Approved by NMPA for Marketing
Tags：
SSY Group02005.HKAPI
2026-02-27
SSY Group (02005.HK): Secures Production Registration Approval for New 2ml Specification of Potassium Dihydrogen Phosphate Complex Injection
Tags：
SSY Group02005.HKdrug production registration approval
2026-01-26
SSY Group (02005.HK): Sodium Glycerophosphate Injection Obtains NMPA Drug Production Registration Approval
Tags：
SSY Group02005.HKNew Drug Update
2025-12-30